Posted: 29 January 2026
Cartherics Pty Ltd has been granted a second patent in China for “Genetically modified cells and uses thereof”, strengthening its intellectual property position for the development of off-the-shelf immune cell therapies focused on high-impact women’s diseases, including ovarian cancer and endometriosis.
“We are pleased to see the issuance of another patent from our first patent family,” said Cartherics Chief Executive Officer Dr Ian Nisbet. “This is a valuable addition to the patent portfolio supporting the development and commercialisation of our off-the-shelf cellular therapies for the treatment of cancer and endometriosis.”
The patent was granted by the Chinese Patent Office and extends Cartherics’ proprietary position for its leading candidate. The claims encompass mammalian stem cells that have been genetically engineered to incorporate the Company’s chimeric antigen receptor (CAR) technology targeting the tumour-associated antigen TAG-72.
The Chinese patent covers essential gene-editing features of the stem cells used in the manufacture of Cartherics’ lead product, CTH-401. The Company is manufacturing product for clinical trials in its newly upgraded clean room facilities and aims to initiate a first-in-human clinical trial in ovarian cancer patients in the second half of 2026.
The granting of the patent in China materially strengthens Cartherics’ global intellectual property portfolio, de-risks future commercialisation, and positions the Company to generate commercial value in a large, rapidly expanding oncology market.
